Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
3.
Dermatol Ther ; 34(2): e14851, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33547869

RESUMO

Hidradenitis suppurativa (HS) is a chronic and often debilitating inflammatory condition characterized by frequent nodules, abscesses, sinus tracts, and scars impacting the intertriginous areas. Many patients with HS often report limited treatment success and symptom coverage with conventional therapies. Recent studies have reported the widespread use of complementary and alternative medicine (CAM) among patients with HS. In this study, our aim was to examine current physician practice patterns, opinions, and comfort with recommending CAM. Our results indicate that provider comfort and opinions on CAM varied based on the provider's experiences, demographics, and the CAM modality itself. Overall, nearly two-thirds (n = 30, 61.2%) of respondents agreed that CAM and conventional medicine were more effective together than either alone. Meanwhile, 44.9% (n = 22) of respondents routinely recommend CAM while 64.6% (n = 31) of respondents reported that they are routinely asked about CAM. The majority (n = 41, 83.7%) of respondents indicated a lack of scientific evidence in the medical literature as a barrier to recommending CAM along with efficacy concerns (n = 34, 69.4%) and ability to recommend reputable CAM products (n = 32, 65.3%) and practitioners (n = 32, 65.3%). Future investigations are warranted to establish a better understanding of the efficacy and benefit of CAM methods in conjunction with conventional methods.


Assuntos
Terapias Complementares , Hidradenite Supurativa , Médicos , Hidradenite Supurativa/diagnóstico , Hidradenite Supurativa/terapia , Humanos , Resultado do Tratamento
4.
J Am Acad Dermatol ; 85(1): 187-199, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32950543

RESUMO

Pain contributes substantially to reduced quality of life in individuals living with hidradenitis suppurativa (HS). Although improved understanding of HS pathogenesis and treatment has resulted in improved evidence-based HS management guidelines, comprehensive pain management guidelines have yet to be developed. Few HS-specific data exist to guide pharmacologic analgesia; however, recognizing HS pain as either acute or chronic and predominantly nociceptive (aching and gnawing pain due to tissue damage) versus neuropathic (burning-type pain due to somatosensory nervous system dysfunction) provides a conceptual framework for applying outside pain management practices to HS management. This article incorporates the best available evidence from the HS and pain literature to propose an HS pain algorithm that integrates psychological, pharmacologic, and complementary and alternative treatment modalities.


Assuntos
Algoritmos , Hidradenite Supurativa/complicações , Neuralgia/terapia , Dor Nociceptiva/terapia , Manejo da Dor/métodos , Analgésicos/uso terapêutico , Anti-Inflamatórios não Esteroides/uso terapêutico , Antidepressivos Tricíclicos/uso terapêutico , Dor Crônica/etiologia , Dor Crônica/psicologia , Dor Crônica/terapia , Terapia Cognitivo-Comportamental , Terapias Complementares , Depressão/etiologia , Depressão/terapia , Humanos , Neuralgia/etiologia , Neuralgia/psicologia , Neurotransmissores/uso terapêutico , Dor Nociceptiva/etiologia , Dor Nociceptiva/psicologia , Guias de Prática Clínica como Assunto
5.
J Am Acad Dermatol ; 81(1): 76-90, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-30872156

RESUMO

Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles, with profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and management of patients with hidradenitis suppurativa is still sparse in many areas, but it has grown substantially in the last decade. Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies, including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options. Recommendations and evidence grading based on the evidence available at the time of the review are provided.


Assuntos
Produtos Biológicos/uso terapêutico , Hidradenite Supurativa/diagnóstico , Hidradenite Supurativa/terapia , Guias de Prática Clínica como Assunto , Antibacterianos , Canadá , Terapias Complementares , Procedimentos Cirúrgicos Dermatológicos/métodos , Quimioterapia Combinada , Medicina Baseada em Evidências , Feminino , Humanos , Imunossupressores/uso terapêutico , Masculino , América do Norte , Editoração , Medição de Risco , Índice de Gravidade de Doença , Estados Unidos
6.
Am J Clin Nutr ; 105(5): 1230-1238, 2017 05.
Artigo em Inglês | MEDLINE | ID: mdl-28228421

RESUMO

Background: Vitamin D deficiency, defined as a serum 25-hydroxyvitamin D [25(OH)D] concentration <20 ng/mL, is correlated with a more atherogenic lipid profile. However, oral vitamin D supplementation does not lower LDL-cholesterol concentrations or raise HDL-cholesterol concentrations. This uncoupling between association and causation may result from a failure of oral vitamin D to mimic the effect of dermally synthesized vitamin D in response to ultraviolet type B (UVB) light.Objective: We tested the hypothesis that, in vitamin D-deficient adults, the replenishment of vitamin D with UVB exposure would lower LDL-cholesterol concentrations compared with the effect of oral vitamin D3 supplementation.Design: We performed a randomized clinical trial in vitamin D-deficient adults and compared vitamin D replenishment between subjects who received oral vitamin D3 (n = 60) and those who received narrow-band UVB exposure (n = 58) ≤6 mo.Results: There was no difference in the change from baseline LDL-cholesterol concentrations between oral vitamin D3 and UVB groups (difference in median of oral vitamin D3 minus that of UVB: 1.5 mg/dL; 95% CI: -5.0, 7.0 mg/dL). There were also no differences within groups or between groups for changes in total or HDL cholesterol or triglycerides. Transcriptional profiling of skin and blood, however, revealed significant upregulation of immune pathway signaling with oral vitamin D3 but significant downregulation with UVB.Conclusions: Correcting vitamin D deficiency with either oral vitamin D3 or UVB does not improve the lipid profile. Beyond cholesterol, these 2 modalities of raising 25(OH)D have disparate effects on gene transcription. This trial was registered at clinicaltrials.gov as NCT01688102.


Assuntos
Colesterol/sangue , Suplementos Nutricionais , Pele/metabolismo , Transcrição Gênica/efeitos dos fármacos , Raios Ultravioleta , Deficiência de Vitamina D/complicações , Vitamina D/farmacologia , Adulto , Colecalciferol/sangue , Colecalciferol/farmacologia , Colecalciferol/uso terapêutico , LDL-Colesterol/sangue , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Sistema Imunitário , Masculino , Pessoa de Meia-Idade , Placa Aterosclerótica/sangue , Placa Aterosclerótica/etiologia , Transdução de Sinais , Pele/efeitos da radiação , Vitamina D/análogos & derivados , Vitamina D/biossíntese , Vitamina D/sangue , Vitamina D/uso terapêutico , Deficiência de Vitamina D/sangue , Deficiência de Vitamina D/tratamento farmacológico , Vitaminas/sangue , Vitaminas/farmacologia , Vitaminas/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA